Prostate cancer: Molecular imaging and MRI

Farshad Moradi; Andrea Farolfi; Stefano Fanti; Andrei Iagaru

doi:10.1016/j.ejrad.2021.109893

Prostate cancer: Molecular imaging and MRI

Eur J Radiol. 2021 Oct:143:109893. doi: 10.1016/j.ejrad.2021.109893. Epub 2021 Aug 6.

Authors

Farshad Moradi¹, Andrea Farolfi², Stefano Fanti², Andrei Iagaru³

Affiliations

¹ Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA. Electronic address: fmoradi@stanford.edu.
² Nuclear Medicine Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
³ Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA.

PMID: 34391061
DOI: 10.1016/j.ejrad.2021.109893

Abstract

The role of molecular imaging in initial evaluation of men with presumed or established diagnosis of prostate cancer and work up of biochemical recurrence and metastatic disease is rapidly evolving due to superior diagnostic performance compared to anatomic imaging. However, variable tumor biology and expression of transmembrane proteins or metabolic alterations poses a challenge. We review the evidence and controversies with emphasis on emerging PET radiopharmaceuticals and experience on clinical utility of PET/CT and PET/MRI in diagnosis and management of prostate cancer.

Keywords: (11)C-Choline; (18)F-DCFPyL; (18)F-Fluciclovine; (68)Ga-PSMA; (68)Ga-RM2; PET/MRI.

Publication types

Review

MeSH terms

Humans
Magnetic Resonance Imaging
Male
Molecular Imaging
Oligopeptides
Positron Emission Tomography Computed Tomography*
Prostatic Neoplasms* / diagnostic imaging
Radiopharmaceuticals

Substances

Oligopeptides
Radiopharmaceuticals